Immunotherapies developed to treat cancer can be adapted to treat autoimmunity.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$99.00 per year
only $8.25 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rosenberg, S. A. et al. N. Engl. J. Med. 313, 1485–1492 (1985).
Ye, C., Brand, D. & Zheng, S. G. Signal Transduct. Target. Ther. 3, 2 (2018).
Klatzmann, D. & Abbas, A. K. Nat. Rev. Immunol. 15, 283–294 (2015).
Long, S. A. et al. Diabetes 61, 2340–2348 (2012).
Boyman, O., Kovar, M., Rubinstein, M. P., Surh, C. D. & Sprent, J. Science 311, 1924–1927 (2006).
Spangler, J. B. et al. J. Immunol. 201, 2094–2106 (2018).
Trotta, E. et al. Nat. Med. 24, 1005–1014 (2018).
Carmenate, T. et al. J. Immunol. 190, 6230–6238 (2013).
Tchao, N. et al. Lup. Sci. Med. 5, abstract.178 (2018).
Dawson, N. A. J., Vent-Schmidt, J. & Levings, M. K. Front. Immunol. 8, 1460 (2017).
Langowski, J. et al. Arthrit. Rheumatol. 69, abstract 2715 (2017).
Amgen. U.S. National Library of Medicine https://clinicaltrials.gov/ct2/show/NCT03451422 (2019).
Nektar Therapeutics. U.S. National Library of Medicine https://clinicaltrials.gov/ct2/show/NCT03556007 (2018).
Amgen. U.S. National Library of Medicine https://clinicaltrials.gov/ct2/show/NCT03410056 (2019).
Sockolosky, J. T. et al. Science 359, 1037–1042 (2018).
Stebbings, R., Poole, S. & Thorpe, R. Curr. Opin. Biotechnol. 20, 673–677 (2009).
Suntharalingam, G. et al. N. Engl. J. Med. 355, 1018–1028 (2006).
Postow, M. A., Sidlow, R. & Hellmann, M. D. N. Engl. J. Med. 378, 158–168 (2018).
Stamatouli, A. M. et al. Diabetes 67, 1471–1480 (2018).
Hughes, J. et al. Diabetes Care 38, 55–57 (2015).
Varricchi, G. et al. Curr. Med. Chem. 25, 1327–1339 (2018).
Wanchoo, R. et al. Am. J. Nephrol. 45, 160–169 (2017).
Samaan, M. A., Pavlidis, P., Papa, S., Powell, N. & Irving, P. M. Nat. Rev. Gastroenterol. Hepatol. 15, 222–234 (2018).
Dougan, M. Front Immunol. 8, 1547 (2017).
Zaitsu, M., Issa, F., Hester, J., Vanhove, B. & Wood, K. J. JCI Insight 2, 89381 (2017).
Watkins, B. K. et al. J. Clin. Invest. 128, 3991–4007 (2018).
Dixon, K. O. et al. J. Immunol. 200, 3000–3007 (2018).
Rigby, M. R. et al. J. Clin. Invest. 125, 3285–3296 (2015).
Long, S. A. et al. Sci. Immunol. 1, eaai7793 (2016).
Chabannon, C. et al. Sci. Transl. Med. 10, eeap9630 (2018).
Blazar, B. R., MacDonald, K. P. A. & Hill, G. R. Blood 131, 2651–2660 (2018).
June, C. H. & Sadelain, M. N. Engl. J. Med. 379, 64–73 (2018).
Elinav, E., Waks, T. & Eshhar, Z. Gastroenterology 134, 2014–2024 (2008).
Fransson, M. et al. J. Neuroinflamm. 9, 112 (2012).
Boardman, D. A. et al. Am. J. Transplant 17, 931–943 (2017).
MacDonald, K. G. et al. J. Clin. Invest. 126, 1413–1424 (2016).
Noyan, F. et al. Am. J. Transplant 17, 917–930 (2017).
Sicard, A., Boardman, D. A. & Levings, M. K. Curr. Opin. Organ Transplant 23, 509–515 (2018).
Pierini, A. et al. JCI Insight 2, e92865 (2017).
Koristka, S. et al. J. Autoimmun. 90, 116–131 (2018).
Sicard, A., Levings, M. K. & Scott, D. W. Am. J. Transplant 18, 1305–1311 (2018).
Ellebrecht, C. T. et al. Science 353, 179–184 (2016).
Geiger, T. L., Nguyen, P., Leitenberg, D. & Flavell, R. A. Blood 98, 2364–2371 (2001).
Zhang, A. H., Yoon, J., Kim, Y. C. & Scott, D. W. J. Immunol. 201, 1434–1441 (2018).
Acknowledgements
The authors’ own work in this area is funded by the Canadian Institutes of Health Research (CIHR), TxCell SA, the Stem Cell Network, BioCanRx and the Helmsley Trust. D.A.B. holds a CIHR fellowship and M.K.L. receives a Scientist Salary Award from the BC Children’s Hospital Research Institute.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.K.L. has received research funding from TxCell, Pfizer and Bristol Myers Squibb, and has patents pending on alloantigen-specific chimaeric antigen receptors.
Rights and permissions
About this article
Cite this article
Boardman, D.A., Levings, M.K. Cancer immunotherapies repurposed for use in autoimmunity. Nat Biomed Eng 3, 259–263 (2019). https://doi.org/10.1038/s41551-019-0359-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41551-019-0359-6
This article is cited by
-
Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer
Cellular & Molecular Immunology (2021)
-
Treg cell-based therapies: challenges and perspectives
Nature Reviews Immunology (2020)